8月22日，波士顿科学盘中上涨3.01%，报50.855美元/股，成交额7.66亿美元。
消息面上，公司近日接连获得中国国家药监局批准：新一代热蒸汽治疗设备Rezūm EVO在华获批，中国成为该产品全球首批获批市场；同时上海临港工厂生产的新一代FARASTAR心脏脉冲电场消融系统也正式获批，从受理到获批创下公司在华本土设备项目最快纪录，较以往同类项目审批周期缩短约1.5个月。两项获批标志着公司本土化生产范围从高端介入耗材拓展至复杂设备平台，为此前因Watchman业务放缓及全年指引下调持续承压的股价带来阶段性修复动力。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.